A Study to Compare Long-Term Safety and Tolerability of Stavudine (d4T) Extended Release (ER) Versus Conventional (Immediate Release, IR) Formulations, Each In Combination With Lamivudine (3TC) and Efavirenz (EFV) in Subjects Who Have Completed BMS Studies AI455-096 and AI455-099.
Latest Information Update: 30 Apr 2011
At a glance
- Drugs Stavudine (Primary) ; Efavirenz; Lamivudine
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 07 Feb 2010 New trial record